SecBot SecBot

CLRB

Cellectar Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001279704 Biotech & Drug Discovery
$1.22 +0.05 (+4.27%)
Oct 23 4:00 PM ET · prev $1.17
Market cap
$11.1M
Nano cap
Median target
🔒 Subscribers only
1 year
−69.5%
from $4.00 · Oct 24
30 days
−41.3%
from $2.08
52-week range
$1.12–4.04
−70% from high · low Oct 19
Avg volume 20D
163.9K
Oct 13 spike 534.5K
Short interest
166.3K
≈1.8% of shares · −13.0%
Days to cover
2.0
at average volume
Insider net
+$50.5K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $50.5K at an average $0.7275. No open-market sales. Price is 68% above their cost.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −13.0% to 166.3K shares. 2.0 days to cover, ≈1.8% of shares.

  • TrendDOWNTREND

    40% below its 50-day average. New closing low $1.12 on Oct 19.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED327,367$910.1K
VANGUARD FIDUCIARY TRUST CODOUBLED46,220$128.5K
UBS Group AGTRIM3,093$8.6K
OSAIC HOLDINGS, INC.DOUBLED7$18.00
GEODE CAPITAL MANAGEMENT, LLCADD52,778$134.1K
Sequoia Financial Advisors, LLCTRIM18,850$47.9K
UBS Group AGDOUBLED9,647$24.5K
OSAIC HOLDINGS, INC.NEAR_EXIT1$2.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Mar 10, 2026Maxim Group
UPGRADE
UPGRADEBuy
May 14, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Dec 11, 2024Oppenheimer
DOWNGRADE
DOWNGRADEPerform
Nov 19, 2024Oppenheimer
MAINTAIN
MAINTAINOutperform
Mar 28, 2024Roth MKM
MAINTAIN
MAINTAINBuy
Mar 28, 2024Oppenheimer
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$50.5K
bought · 2 insiders
$0
sold · 0 insiders
+67.7%
vs their $0.7275 cost
DateInsiderTypeValue
Jul 8, 2026
Loren Stefan
AWARD15,000 sh
Jul 7, 2026
NEIS JOHN
Director
AWARD25,000 sh
Jul 7, 2026
Swirsky Douglas J
Director
AWARD37,500 sh
Jul 7, 2026
Longcor Jarrod
Chief Operating Officer
AWARD118,000 sh
Jul 7, 2026
Gu Andrew
Director
AWARD25,000 sh
Jul 7, 2026
CARUSO JAMES V
President & CEO
AWARD250,000 sh
Jul 7, 2026
Chanan-Khan Asher
Director
AWARD25,000 sh
Jul 7, 2026
DRISCOLL FREDERICK W
Director
AWARD25,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/pennystocks Neutral 1d ago
I'm pretty heavy in on CLRB what's your thought on that one?
All social signals and their track records

Short side

FINRA· Sep 30, 2026
166,265
shares short
-13.0%
vs prior settlement
2.0
days to cover
≈1.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Press
Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in…
Impact 6/10
Oct 15, 2026 FDA
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immedia
Aug 13, 2026 SEC
Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D…
PRESS-RELEASE — Impact 4/10
Aug 13, 2026 SEC
Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D…
8-K — Impact 4/10
Jul 8, 2026 Insider
Loren Stefan was granted 15,000 shares
Jul 7, 2026 Insider
NEIS JOHN was granted 25,000 shares
Director
Jul 7, 2026 Insider
Swirsky Douglas J was granted 37,500 shares
Director
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
327,367 shares ($910.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 15, 2026
FDA
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5%…
Aug 13, 2026
Earnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the…
Aug 12, 2026
Earnings date
CLRB Q2 2026 Earnings Scheduled — 2026-08-12
Jul 30, 2026
Earnings
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company…
Jun 1, 2026
FDA
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131…

SecBot reports

12 filings · 5 press releases · 1 bullish · 5 bearish · 1 mixed · 5 neutral
All CLRB filing & press-release reports (17)